NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be ...
Presentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174 The SGR-3515 presentation will include data demonstrating that an optimized, intermittent dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback